PROGRAMME EHMSG Workshop
Friday, September 8, 2023
08.00 – 10.00 hrs Session 1: What’s happening in H.pylori and gut microbiota
Chair: Annemieke Smet, Belgium, Christian Schulz, Germany
Room "Okapi"
08.00 – 08.20
01.01. Microbiome predicting the development of diseases in the population
Rinse Weersma, Groningen, The Netherlands
08.20 – 08.40
01.02. Helicobacter pylori: a stealth assassin
Richard Peek, Nashville, TN, USA
08.40 – 09.00
01.03. Breakthroughs and bottlenecks in microbiome research
Marie Joossens, Ghent, Belgium
09.00 – 09.20
01.04. Microbiota testing
Gianluca Ianiro, Rome, Italy
09.20 – 09.40
01.05. Impact of H. pylori eradication on gut microbiota
Jyhming Liou, Taipei, Taiwan
09.40 – 10.00
01.06. Gastric cancer and metabolomic profile
Jun-Young Seo, Seoul, Korea
10.00 - 10.30 hrs Coffee Break
Room "Atrium" - Exhibition & Poster Area
10.30 – 12.30 hrs Session 2: News on gastritis (Parallel Session)
Chair: Ari Ristimäki, Finland, Theodore Rokkas, Greece
Room "Okapi"
10.30 – 10.50
02.01. The evolution in gastritis classification - the REGAIN initiative
Massimo Rugge, Padua, Italy
10.50 – 11.10
02.02. H. pylori and its crosstalk to other gastric bacteria
Christian Schulz, Munich, Germany
11.10 – 11.30
02.03. The role of H. pylori and other microorganisms in autoimmune gastritis
Emanuele Dilaghi, Roma, Italy
11.30 – 11.50
02.04. New developments and directions in protection against gastric disease and cancer
Thomas Boren, Umea, Sweden
11.50 – 12.02
02.05. GastroPanel, Ghrelin and Leptin for non-invasive diagnosis of advanced gastric atrophy and intestinal Metaplasia
Lukas Macke, Munich, Germany
12.02 – 12.14
02.06. Real-time gastric juice analysis for detection of Helicobacter pylori infection: is it useful in daily clinical practice?
André Trigo, Coimbra, Portugal
12.14 – 12.26
02.07. Gastric pathology and Helicobacter pylori vacA genotype in Indigenous communities of Arctic Canada
Taylor Cromarty, Edmonton, Canada
10.30 – 12.30 hrs Session 3: Microbiome mechanisms of action (Parallel Session)
Chair: Mirjana Rajilić-Stojanović, Serbia, Lars Engstrand, Sweden
Room "Gorilla"
10.30 – 10.50
03.01. Oncobiome
Jorge Galena Nino, Seattle, WA, USA
10.50 – 11.10
03.02. Using tools to make predictions
Tove Fall, Uppsala, Sweden
11.10 – 11.30
03.03. Microbial manipulation using model systems
Georgina Hold, Sydney, Australia
11.30 – 11.50
03.04. Dietary manipulation and its influence on microbial communities
Jeongseon Kim, Goyang-si, Korea
11.50 – 12.02
03.05. Mouth microbiome in children with autism: diagnosis-related differences and associations with behavioral difficulties
Margaux Evenepoel, Leuven, Belgium
12.02 – 12.14
03.06. KvarM lowers Klebsiella pneumoniae colonization in gastrointestinal tract without disruption of gut Microbiota
Indre Karaliute, Kaunas, Lithuania
12.14 – 12.26
03.07. Gut-vagina axis: Diet is associated with the vaginal microbiome
Isabell Erreygers, Antwerp, Belgium
12.30 – 14.00 hrs Lunch Break & Poster Viewing
Room "Atrium" - Exhibition & Poster Area
14.00 - 16.00 Session 4: Helicobacter pylori Genome Project (HpGP) (Parallel Session)
Chair: Constanza Camargo, USA, Juozas Kupcinskas, Lithuania
Room "Gorilla"
14.00 – 14.10
04.01. Overview of HpGP
Constanza Camargo, Rockville, MD, USA
14.10 – 14.30
04.02. New insights into Helicobacter pylori population structure from the HpGP
Kaisa Thorell, Gothenburg, Sweden
14.30 – 14.50
04.03. Disclosing prophage genomics in the HpGP
Filipa Vale, Lisbon, Portugal
14.50 – 15.10
04.04. Identification and characterization of plasmids in Helicobacter pylori
Roberto Torres, Shanghai, China
15.10 – 15.30
04.05. The DNA methylases found in Helicobacter pylori strains
Rick Morgan, Ipswich, MA, USA
15.30 – 15.45
Q&A – participation of all HpGP investigators
15.45 – 16.00
04.06. Comprehensive analysis of Integrating Conjugative Elements (ICEs) in Helicobacter pylori populations
Wolfgang Fischer, Munich, Germany
14.00 - 16.00 hrs Session 5: Microbiota modulation for a healthy life (Parallel Session)
Chair: Georgina Hold, Australia, Marie Joossens, Belgium
Room "Okapi"
14.00 – 14.20
05.01. Diet and lifestyle
Francesco Franceschi, Rome, Italy
14.20 – 14.40
05.02. Pre- and Probiotics
Mirjana Rajilić-Stojanović, Belgrade, Serbia
14.40 – 15.00
05.03. Postbiotics
Tom Van de Wiele, Ghent, Belgium
15.00 – 15.20
05.04. Antibiotics
Antonio Gasbarrini, Rome, Italy
15.20 – 15.32
05.05. Composition of infant gut virome associated with maternal antibacterial therapy and type of delivery
Egija Zelča, Riga, Latvia
15.32 – 15.44
05.06. Long-term outcomes of oral antibiotics combination therapy for induction and maintenance of ulcerative colitis
Toshifufi Ohkusa, Tokyo, Japan
15.44 – 15.56
05.07. Perceptions and practices on clinical use of probiotics: a national survey of healthcare practitioners.
Vasilios Papastergiou, Athens, Greece
16.00 - 16.30 hrs Coffee Break
Room "Atrium" - Exhibition & Poster Area
16.30 - 18.30 hrs Session 6: Gastric Carcinogenesis (Parallel Session)
Chair: José Machado, Portugal, Hwoon-Yong Jung, Korea
Room "Okapi"
16.30 – 16.50
06.01. A single H. pylori SNP controlling gastric cancer development
Steffen Backert, Erlangen, Germany
16.50 – 17.10
06.02. Cellular differentiation and neoplastic transformation of the gastric mucosa
Michael Sigal, Berlin, Germany
17.10 – 17.30
06.03. Gastric Cancer stem cells and metastasis
Christine Varon, Bordeaux, France
17.30 – 17.50
06.04. Impact of H. pylori infection on cancer immunotherapies
Dominique Velin, Lausanne, Switzerland
17.50 – 18.02
06.05. The humanized Leb mouse model with gastric cancer caused by life-long H. pylori infection
Artem Piddubnyi, Umea, Sweden
18.02 – 18.14
06.06. Study of Lactobacillus spp. effects on gastric carcinogenesis in the context of Helicobacter pylori Infection
Marine Jauvain, Bordeaux, France
18.14 – 18.26
06.07. Beneficial effect of sodium hydrosulfide, the hydrogen sulfide (H2S) donor on Helicobacter pylori (Hp)-infected fibroblasts in vitro. A key to therapeutic inhibition of Hp-carcinogenesis?
Tomasz Brzozowski, Cracow, Poland
16.30 - 18.30 hrs Session 7: Microbiota modulation by FMT (Parallel Session)
Chair: Gianluca Ianiro, Italy, Josbert Keller, The Netherlands
Room "Gorilla"
16.30 – 16.50
07.01. FMT beyond Clostridioides difficile
Josbert Keller, Leiden, The Netherlands
16.50 – 17.10
07.02. FMT preparations: modification, lyophylization, or spores
Christian Hvas, Aarhus, Denmark
17.10 – 17.20
07.03. Safety of FMT and prospective registries
Maria Vehreschild, Frankfurt, Germany
17.20 – 17.35
07.04. Gastric microbiome modulation via FMT and immunity
Juan Du, Solna, Sweden
17.35 – 17.50
07.05. Factors underlying FMT efficacy
Harry Sokol, Paris, France
17.50 – 18.02
07.06. Double-blinded randomized controlled trial assessing the effect of triple faecal microbiota transplantation on hepatic steatosis in patients with non-alcoholic fatty liver disease
Bas Groenewegen, Leiden, The Netherlands
18.02 – 18.14
07.07. Comparative Efficacy of Encapsulated Fecal Microbiota Transplantation (FMT) and FMT via rectal enema for Irritable Bowel Syndrome (IBS): A Double-blind, Randomized, Placebo-controlled study (CAP-ENEMA FMT Trial)
Ratha-korn Vilaichone, Pathumthani, Thailand
18.14 – 18.26
07.08. Mycobial community in monozygotic and dizygotic twins
Konrad Lehr, Magdeburg, Germany
20.00 hrs Networking Dinner
Saturday, September 9, 2023
08.30 – 09.00 hrs Session 8: Memorial Talks
Chair: Annemieke Smet
Room "Okapi"
08.30 – 08.45
08.01. In Memoriam Michel Deltenre
Ruffin Ntounda, Brussels, Belgium
08.45 – 09.00
08.02. In Memoriam Jose Pajares
Javier Gisbert, Madrid, Spain
09.00 - 11.00 hrs Session 9: H pylori management (Parallel Session)
Chair: Javier Gisbert, Spain, Colm O’Morain, Ireland
Room "Okapi"
09.00 – 09.20
09.01. The search for new drug targets and therapies
Sinead Smith, Dublin, Ireland
09.20 – 09.40
09.02. Lessons from the first 10 years from the European registry
Olga Nyssen, Madrid, Spain
09.40 – 10.00
09.03. Integration of antimicrobial susceptibility testing
David Graham, Houston, TX, USA
10.00 – 10.20
09.04. Personalised eradication treatment in Korea
Seong Woo Jeon, Daegu, Korea
10.20 – 10.32
09.05. Use of machine learning models to predict failure of Helicobacter pylori eradication therapy: A two country validation study
Wai Leung, Hong Kong
10.32 – 10.44
09.06. Susceptibility guided treatment of Helicobacter pylori infection: Serbian study experience
Vladimir Milivojevic, Belgrade, Serbia
10.44 – 10.56
09.07. Rifabutin-containing triple therapy versus bismuth quadruple therapy for Helicobacter pylori rescue treatment: a Multicenter, randomized controlled trial
Hong Lu, Shanghai, China
09.00 - 11.00 hrs Session 10: Diseases & Microbiota (Parallel Session)
Chair: Francesco Franceschi, Italy, Jae Gyu Kim, Korea
Room "Gorilla"
09.00 – 09.20
10.01. Gastric cancer and microbiota
Emilie Bessède, Bordeaux, France
09.20 – 09.45
10.02. Mycobiota in cancer
Alexander Link, Magdeburg, Germany
09.45 - 10.10
10.03. Leaky gut and circulating microbiome
Juozas Kupcinskas, Kaunas, Lithuania
10.10. - 10.26
10.05. CagA determines the microbiome changes and risk of colorectal cancer elicited by Helicobacter pylori infection
Veronika Engelsberger, Munich, Germany
10.26 - 10.42
10.06. Lactobacillus - a new key player in gastric carcinogenesis?
Karla Vinasco, Kensington, Australia
10.42 - 10.58
10.07. Urinary lithogenic profile and gut and urinary microbiota in patients with inflammatory bowel disease
Irene Mignini, Rome, Italy
11.00 - 11.30 hrs Coffee Break
Room "Atrium" - Exhibition & Poster Area
11.30 – 12.30 hrs Session 11 - Industry Sponsored Satellite Symposium
Chair: Colm O'Morain, Ireland
Room "Okapi"
Please click HERE to view the detailed programme
12.30 – 14.30 hrs Lunch Break & Poster Viewing
Room "Atrium" - Exhibition & Poster Area
14.30 - 15.30 hrs Session 12: Debates – Search for the truth
Chair: Yaron Niv, Israel, Jan Tack, Belgium
Room "Okapi"
14.30 – 14.50
H.pylori is a protective factor for oesophageal disease
14.30 – 14.40 12.01. Yes: Theodore Rokkas, Athens, Greece
14.40 – 14.50 12.02. No: Jan Bornschein, Oxford, United Kingdom
14.50 – 15.10
Acid suppression can cause gastric cancer
14.50 – 15.00 12.03. Yes: Chan Hyuk Park, Seoul, Korea
15.00 – 15.10 12.04. No: Peter Malfertheiner, Munich, Germany
15.10 – 15.30
Microbiota in IBS: Chicken or egg?
15.10 – 15.20 12.05. Sébastien Kindt, Brussels, Belgium
15.20 – 15.30 12.06. Heiko de Schepper, Antwerp, Belgium
15.30 - 17.20 hrs Session 13: Updates in Helicobacter & Microbiota
Chair: Marcis Leja, Latvia, Peter Malfertheiner, Germany
Room "Okapi"
15.30 – 15.50
13.01. Carcinogenesis and Lymphomagenesis - basic aspects
Mario D’Elios, Siena, Italy
15.50 – 16.10
13.02. Carcinogenesis and Lymphomagenesis - clinical aspects
Tamara Matysiak, Nantes, France
16.10 – 16.30
13.03. Gut microbiota and functional bowel disease
Jan Tack, Leuven, Belgium
16.30 – 16.50
13.04. Microbiota in reproductive health
Sarah Lebeer, Antwerp, Belgium
16.50 – 17.20
Clinical applications of gut microbiota (Tandem Talk)
16.50 – 17.05 13.05. Francis Chan, Hong Kong, China
17.05 – 17.20 13.06. Siew Ng, Hong Kong, China
17.20 - 18.30 hrs Session 14: Closing Session
Chair: Annemieke Smet, Belgium & Francis Mégraud, France, José Machado, Portugal
Room "Okapi"
17.20 – 17.35
14.01. Genome and methylome variation in Helicobacter pylori infection - Relevance for Disease, Antibiotic Resistance and Vaccine Development
Sebastian Suerbaum, Munich, Germany
17.35 – 17.50
14.02. A world without H. pylori
Barry Marshall, Australia
17.50 – 18.00
14.03. Awarding of the Marshall and Warren Medal 2023 to Youri Glupczynski, Brussels, Belgium
Francis Mégraud, France & Barry Marshall, Australia
18.00 – 18.10
14.04. Presentation of the Journal & Awarding of the best paper
Francesco Franceschi, Rome, Italy
18.10 – 18.20
14.05. Awarding of the EHMSG Oral and Poster Awards
18.20 – 18.30
14.06. Presentation of the next meeting in Porto, Portugal
José Machado, Porto, Portugal
Closing Remarks